Transfusion Biology and Cellular Therapies

输血生物学和细胞疗法

• 批准号: 10555517
• 负责人: JOHN P MANIS
• 金额: $ 65.42万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-01 至 2027-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10555517
• 关键词: Biology; Cell Therapy; Transfusion

PROJECT SUMMARY For the past century, a major focus for Transfusion Medicine has been the immune compatibility of blood components with added attention to the safe and appropriate use of blood products. The success of these investigations has fueled expansive growth in the field with efforts focused on developing novel blood components for transfusion and to generate cellular therapies. These activities require a concerted effort to link advances in basic science with therapeutic interventions in the clinic. Transfusion Medicine Scientists and Specialists lead the effort to train individuals to advance blood and hematopoietic cellular therapies. The overall goal of the Program in Transfusion Biology and Cellular Therapies continues to be the preparation of M.D., M.D./Ph.D. or Ph.D. postdoctoral fellows for biomedical research careers. This long-standing program entering its third decade has supported 80 postdoctoral fellows with over 40% of trainees being women or underrepresented individuals. The T32 supports 8 postdoctoral fellows for 2-3 years enabling them to move on to leading positions in academia or industry. As the field of Transfusion Medicine continues to grow, as does the program to include the scientific areas around Immunobiology, Hematopoiesis, and Cellular Therapy. Major strengths of our multi-disciplinary program include utilizing the strong clinical and basic research environments at Harvard Medical School involving Boston Children's Hospital, Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital. In addition to scientific investigation, we have developed programs to a) educate trainees in responsible conduct of research, grant writing, laboratory management, and ensuring rigor and reproducibility of data b) offer opportunities to develop skills in public speaking c) recruit and retain trainees from underrepresented or disadvantaged groups and d) maintain academic oversight for scholarship to advance career development. Dr. John Manis will continue his role as overall PI and has expanded the number of Program co-Directors to effectively represent both basic science and clinical Transfusion Medicine. These leaders will be responsible for the scientific direction of the training program, the mentoring of trainees as well as junior faculty, and monitoring milestones to ensure continued success. We have assembled our faculty roster this year to increase contemporary scientific representation from disciplines related to Transfusion and to better reflect the needs of our applicant pool. We believe our approach of including broad representation of clinical, basic and translational research talent is a fundamental strength of our program and fits well with the evolving field of Transfusion Biology and Cellular Therapies. This distinctive training approach has generated a unique environment for trainees in the Harvard Medical Area and ours remains a highly sought-after program. The outstanding pool of applicants and recruitment of faculty dedicated to the program has facilitated this goal. Our evolving Training Program strives to provide a unique and rich training environment for academic transfusion biology and cellular therapies.

项目摘要 在过去的世纪，输血医学的一个主要焦点是血液的免疫相容性 血液制品的安全和适当使用。圆满成功之 研究已经推动了该领域的广泛发展，努力开发新型血液 用于输血和产生细胞疗法的组件。这些活动需要作出协调一致的努力， 基础科学的进步与临床治疗干预。输血医学科学家和 专家领导的努力，培训个人推进血液和造血细胞疗法。的 在输血生物学和细胞治疗方案的总体目标仍然是准备 医学博士，医学博士/博士或博士博士后研究员的生物医学研究事业。这个长期的计划 进入第三个十年，支持了80名博士后研究员，其中40%以上的受训人员是妇女， 代表性不足的个人。T32支持8名博士后研究员2-3年，使他们能够继续前进 在学术界或工业界的领导地位。随着输血医学领域的不断发展， 该计划包括围绕免疫生物学，造血和细胞治疗的科学领域。主要 我们的多学科计划的优势包括利用强大的临床和基础研究环境 在哈佛医学院，涉及波士顿儿童医院，达纳法伯癌症研究所，布里格姆和 妇女医院和马萨诸塞州总医院。除了科学研究，我们 制定方案，a）教育受训人员负责任地进行研究，撰写赠款，实验室 管理，并确保数据的严谨性和可重复性B）提供了在公共场合发展技能的机会 c）从代表性不足或处境不利的群体中招聘和留住受训人员，d）保持 学术监督奖学金，以促进职业发展。约翰·马尼斯博士将继续担任 总体PI，并扩大了计划共同主任的数量，以有效地代表基础科学和 临床输血医学这些领导人将负责培训的科学方向 计划，指导学员以及初级教师，并监测里程碑，以确保持续 成功我们已经收集了我们的教师名册，今年以增加当代科学的代表性 从学科相关的输血，以更好地反映我们的申请人池的需求。我们相信我们的 包括临床，基础和转化研究人才的广泛代表性的方法是一个基本的 我们的计划的优势，并适合与输血生物学和细胞治疗的不断发展的领域。这 独特的培训方法为哈佛医学区的学员创造了独特的环境， 我们的项目仍然非常受欢迎。优秀的申请者和教师招聘 致力于该计划促进了这一目标。我们不断发展的培训计划致力于提供一个独特的 以及丰富的学术输血生物学和细胞疗法培训环境。